Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

NCT05298683 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.

NCT NCT05298683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05298683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Lead sponsor
Hellenic Society of Hematology
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2022
Completion date
January 31, 2026
Enrollment
108 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

blood protein disorders, hematologic diseases, multiple myeloma, neoplasms, neoplasms by histologic type, neoplasms, plasma cell, paraproteinemias, renal impairment